NAD+ (Nicotinamide Adenine Dinucleotide)
Cellular coenzyme (not a peptide) central to energy metabolism; NAD+ itself is not an approved drug; oral precursors NR/NMN studied; IV NAD+ marketed in wellness settings without outcome trials for anti-ageing.
60-Second Scientific Briefing
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell, essential for energy metabolism and DNA-repair enzymes; it is not a peptide. Levels decline with age, which has driven "NAD+ boosting" with oral precursors (NR, NMN) and intravenous NAD+ in wellness clinics. A 2026 systematic review found that oral precursors raise NAD-related markers and are well tolerated, but effects on health outcomes are inconsistent, and no outcome trial has tested intravenous NAD+ for anti-ageing or wellness.
What is NAD+ (Nicotinamide Adenine Dinucleotide)?
Pharmacological Classification & Molecular IdentityNAD+ is a coenzyme present in all cells that carries electrons in energy metabolism and is the substrate of sirtuin and PARP enzymes. Its levels decline with age. It is a dinucleotide, not a peptide. [1] Ageing Res Rev, 2026 ↗
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingReceptor Selectivity: Acts as a coenzyme for redox reactions in energy metabolism and as the substrate consumed by sirtuins and PARP DNA-repair enzymes; it does not act through a receptor. "NAD+ boosting" aims to restore age-related declines. [1] Ageing Res Rev, 2026 ↗
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsNAD+ is not an approved drug for anti-ageing, wellness or other indications. Oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are studied as supplements, and intravenous NAD+ is offered in some wellness settings without outcome trials for those uses (systematic review 2026). [1] Ageing Res Rev, 2026 ↗
NAD+ (Nicotinamide Adenine Dinucleotide) is not approved for commercial sale, prescription therapy, or compounded medication distribution. It exists strictly within authorized scientific and clinical research frameworks.
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesSystematic review (Ageing Res Rev 2026): 113 studies (2010–2025), including 33 human intervention studies (28 randomised); oral NR and NMN consistently raised NAD-related metabolites and were well tolerated over weeks to months, but effects on functional, metabolic, vascular and other healthspan outcomes were heterogeneous and often null; no eligible outcome trial evaluated intravenous or intramuscular NAD+ itself for anti-ageing or wellness. A single-centre randomised trial (2026) in 180 adults with heart failure from ischaemic cardiomyopathy found a greater improvement in ejection fraction at 1 month with 7 days of intravenous NAD+ than placebo (45.4% vs 42.4%, P=0.024), with non-significant trends in clinical events. [1] Ageing Res Rev, 2026 ↗ [2] Am J Cardiovasc Drugs, 2026 ↗
Clinical Evidence
Systematic review (Ageing Res Rev 2026): 113 studies (2010–2025), including 33 human intervention studies (28 randomised); oral NR and NMN consistently raised NAD-related metabolites and were well tolerated over weeks to months, but effects on functional, metabolic, vascular and other healthspan outcomes were heterogeneous and often null; no eligible outcome trial evaluated intravenous or intramuscular NAD+ itself for anti-ageing or wellness. A single-centre randomised trial (2026) in 180 adults with heart failure from ischaemic cardiomyopathy found a greater improvement in ejection fraction at 1 month with 7 days of intravenous NAD+ than placebo (45.4% vs 42.4%, P=0.024), with non-significant trends in clinical events.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesOral precursors were generally well tolerated in trials lasting weeks to months. For intravenous NAD+, the 2026 review found only short-term pilot safety and pharmacokinetic data and no outcome trials. [1] Ageing Res Rev, 2026 ↗
Clinical benefit for ageing or wellness is not established; the heart-failure trial was small and single-centre; the long-term safety of repeated intravenous NAD+ is unknown. [1] Ageing Res Rev, 2026 ↗
Dose Approval Status
Commercial Dosing Status and Policy DirectivesNo dose is approved or established. The amounts used in the published studies are part of each study's design and are described in the linked papers; they are not a recommendation. [1] Ageing Res Rev, 2026 ↗
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- NAD+ is a coenzyme present in all cells that carries electrons in energy metabolism and is the substrate of sirtuin and PARP enzymes. Its levels decline with age. It is a dinucleotide, not a peptide.
- Targets & Selectivity: Acts as a coenzyme for redox reactions in energy metabolism and as the substrate consumed by sirtuins and PARP DNA-repair enzymes; it does not act through a receptor. "NAD+ boosting" aims to restore age-related declines.
- Systematic review (Ageing Res Rev 2026): 113 studies (2010–2025), including 33 human intervention studies (28 randomised); oral NR and NMN consistently raised NAD-related metabolites and were well tolerated over weeks to months, but effects on functional, metabolic, vascular and other healthspan outcomes were heterogeneous and often null; no eligible outcome trial evaluated intravenous or intramuscular NAD+ itself for anti-ageing or wellness. A single-centre randomised trial (2026) in 180 adults with heart failure from ischaemic cardiomyopathy found a greater improvement in ejection fraction at 1 month with 7 days of intravenous NAD+ than placebo (45.4% vs 42.4%, P=0.024), with non-significant trends in clinical events.
- Safety considerations: Oral precursors were generally well tolerated in trials lasting weeks to months. For intravenous NAD+, the 2026 review found only short-term pilot safety and pharmacokinetic data and no outcome trials.
? Unknown / Under Ongoing Investigation
- Clinical benefit for ageing or wellness is not established; the heart-failure trial was small and single-centre; the long-term safety of repeated intravenous NAD+ is unknown.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysNAD+ is a coenzyme in every cell, needed for energy metabolism and DNA-repair enzymes. It is not a peptide and not an approved drug; levels fall with age, which drives "NAD+ boosting" products.
What is the mechanism of action and receptor profile of NAD+ (Nicotinamide Adenine Dinucleotide)?
§It carries electrons in energy metabolism and is consumed by sirtuins and PARP DNA-repair enzymes. It does not act on a receptor.
No. NAD+ is not an approved drug for anti-ageing, wellness or other uses. Oral precursors are sold as supplements, and IV NAD+ is offered in wellness settings without outcome trials for those uses.
A 2026 systematic review (33 human studies) found oral precursors raise NAD markers but have inconsistent, often null effects on health outcomes, and no outcome trial of IV NAD+ for anti-ageing. One small 2026 trial in heart failure reported a modest ejection-fraction gain.
Ageing Res Rev 2026 (PRISMA systematic review, January 2010–October 2025): 113 eligible studies, 33 in humans (28 randomised) and 80 in rodents. In humans, oral NR and NMN raised circulating or cellular NAD-related metabolites and were well tolerated, but effects on functional, metabolic, vascular and other healthspan outcomes were heterogeneous and often null. No eligible outcome trial evaluated intravenous or intramuscular NAD+ for anti-ageing or wellness; only a nonrandomised IV NMN study and an IV NAD+ pharmacokinetic pilot were found. Am J Cardiovasc Drugs 2026: 180 adults with ischaemic cardiomyopathy (ejection fraction 45% or less) received intravenous NAD+ or placebo for 7 days with standard therapy; ejection fraction at 1 month was 45.4% vs 42.4% (P=0.024); 6-month major events 14.6% vs 24.7% (P=0.089, not significant).
- NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence (Ageing Res Rev, 2026-04-01)
- Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial (Am J Cardiovasc Drugs, 2026-01-01)
What adverse effects and safety risks are documented for NAD+ (Nicotinamide Adenine Dinucleotide)?
§Oral precursors were generally well tolerated in trials of weeks to months. For intravenous NAD+, only short-term pilot safety data exist and there are no outcome trials.
What are the critical unknown safety aspects and clinical limitations of NAD+ (Nicotinamide Adenine Dinucleotide)?
§Clinical benefit for ageing or wellness is not established, the heart-failure trial was small and single-centre, and the long-term safety of repeated IV NAD+ is unknown.
No dose is approved or established. The amounts used in the published studies are part of each study's design and are described in the linked papers; they are not a recommendation.
There is no approved drug label; supplement storage follows each product's packaging.
NAD+ itself is not named on the 2026 WADA Prohibited List. Separately, WADA prohibits intravenous infusions or injections of more than a total of 100 mL per 12-hour period (method M2.2), except those legitimately received in hospital treatment, surgery or clinical diagnostic investigations.
- WADA Prohibited List (World Anti-Doping Agency)
What is Egypt Peptides' official medical policy regarding NAD+ (Nicotinamide Adenine Dinucleotide)?
§Egypt Peptides publishes reviewed scientific reference monographs for documentation and research. The site does not give individual medical advice, preparation or injection instructions, combination protocols or off-label use instructions. Decisions about any medicine belong to the treating physician.
NAD+ (Nicotinamide Adenine Dinucleotide) available in Egypt
For research use onlyResearch products with the current store price and stock. The scientific information on this page describes published studies, not these products.
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and published studiesNAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence ↗
https://pubmed.ncbi.nlm.nih.gov/41655607/
Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial ↗
https://pubmed.ncbi.nlm.nih.gov/40954388/